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Abstract
Background: K-ras gene mutations are common in patients with pancreatic cancer (PC); however, their prognostic
value for PC remains inconclusive. This meta-analysis was performed to quantitatively evaluate the association
between K-ras mutations and survival in patients with pancreatic cancer.
Methods: We performed a comprehensive search of electronic sources including MEDLINE (via PubMed), Web of
Science, and the Cochrane Library. The search covered a publication period from inception to November 2015.
Results: Seventeen studies with a total of 2249 patients with pancreatic cancer were included in the tissue detection
of this study. The meta-analysis indicated a significant association between mutant K-ras genes and overall survival (OS)
(HR = 1.51, 95 % CI 1.32–1.72, P < 0.001). Moreover, further subgroup analyses by ethnicity, publication year, therapy
method, cancer resectability, and gene detection method all revealed that pancreatic cancer patients with the K-ras
mutation had significantly poorer OS (P < 0.05). And results from four studies with 225 patients focused on plasma K-ras
mutations enhanced such association (HR = 2.23, 95 % CI 1.69–2.95, P < 0.001).
Conclusions: As a prediction of poor prognosis, the detection of K-ras mutations may be a useful prognostic factor for
pancreatic cancer patients.
Keywords: K-ras, Pancreatic cancer, Prognosis, Meta-analysis
Core tip
To our knowledge, this is the first meta-analysis of all
eligible studies on the prognostic role of the K-ras muta-
tion in patients with pancreatic cancer. In populations of
both Caucasian and Asian descent, patients with pancre-
atic cancer harboring K-ras mutations tend to get a
worse survival. K-ras mutations may represent a useful
prognostic factor to stratify patients with high risk and
develop specific treatments for these patients in clinical
applications.
Background
Pancreatic cancer (PC) has a 5-year survival rate of less
than 5 %, is one of the most aggressive malignancies,
and represents a leading cause of cancer-related mortal-
ity [1, 2]. Most patients were diagnosed when they got
jaundice, and imaging examination was the most effect-
ive diagnosis tool; however, those patients may get an
advanced stage and even lost the opportunity for oper-
ation, as operation is still the only effective treatment for
PC. What is more, even patients received a curative op-
eration, the prognosis is still unsatisfactory.
As a member of the Ras gene family, K-ras plays a key
role in Ras/mitogen-activated protein kinase signaling.
Somatic mutation in K-ras mutations have been shown
to be early events in the carcinogenesis of human pan-
creatic cancer [3, 4]. Approximately 80 % of K-ras muta-
tions in pancreatic cancer involve codon 12; others are
located in codons 13, 61, and 1 [5–7]. K-ras mutations
have been demonstrated to enhance cellular proliferation
and induce malignant transformation, and their continu-
ous activation played a key role in the development and
maintenance of pancreatic cancer [8].
Recent meta-analyses have suggested that K-ras muta-
tions can be used as useful biomarkers for the early detec-
tion of pancreatic cancer [9, 10]. It has been reported
positive in about 65 % patients with PC. Although it
expressed in most pancreatic cancer patients, a sensitivity
of 65 %, sometimes even lower to 36 %, limits its diagnosis
* Correspondence: xiudianrong123@sina.com
Department of General Surgery, Peking University Third Hospital, No. 49, Hua
Yuan North Rd, Hai Dian District, Beijing 100191, China
© 2016 Tao et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Tao et al. World Journal of Surgical Oncology  (2016) 14:146 
DOI 10.1186/s12957-016-0888-3
application [9, 10]. However, its application in the predica-
tion of prognosis and guidance of treatment may be much
more valuable. Although many recent studies evaluated
K-ras gene mutations that appeared to influence the prog-
nosis and patterns of gene expression [11, 12], the use of
K-ras mutations as a prognostic factor for pancreatic
cancer remains inconclusive. To clarify the role of K-
ras mutations in the prognosis of pancreatic cancer, we
performed the present comprehensive meta-analysis.
The detection sources could be tissues or plasma, we
tend to explore both of the sources respectively. To our
knowledge, this study was the first meta-analysis of all
eligible studies on the prognostic role of the K-ras mu-
tation in patients with pancreatic cancer.
Methods
Literature search
A systematic literature search was carried out in MED-
LINE (via PubMed), Web of Science, and the Cochrane
Library to screen for cohort/case-control studies charac-
terizing the association between K-ras mutation and prog-
nosis in PC patient. The search terms were pancreatic or
pancreas neoplasms, ras or K-ras gene, survival, and
prognosis, which covered the publication period from
inception to November 2015. The meta-analysis was
performed using the STATA statistical software. Review
articles were also screened to search for relevant ori-
ginal studies. Only articles published in English were
included in our meta-analysis.
Study selection criteria
Studies deal with the comparison between PC patient with
and without K-ras mutation fulfilling the following criteria
were considered to satisfy the inclusion criteria of present
study: (1) cohort studies, nested case-control studies, or
case-control studies focusing on the prognostic value of
K-ras mutant type in patients with pancreatic cancer;
(2) gene amplification status of K-ras was detected in
surgical or plasma specimens; (3) all patient diagnoses
of pancreatic cancer were confirmed through histopatho-
logic detection; (4) sufficient data were provided to calcu-
late hazard ratios (HR) for OS comparing mutant K-ras
with wild-type K-ras patients; and (5) more than ten pa-
tient samples with K-ras mutation were included in the
original studies because small sample size may be vulner-
able to selection bias. If more than one study by the same
authors (using the same case series) was published, the
study with the largest sample size was included. The data
collected from surgical tissues and plasma specimens were
divided in two different groups and analyzed, respectively.
Data extraction and methodological quality assessment
Two reviewers (LY Tao and LF Zhang) firstly screened
the titles and/or abstracts of all articles independently;
we resolved cases with any disagreements through dis-
cussion and careful reexaminations. The following vari-
ables from studies were extracted with a pre-designed
spreadsheet: first author, year of publication, source of
publication, country, patients’ ethnicity, study design,
total number of cases, detection method of K-ras expres-
sion, mutated sites, treatment method, and OS. Quality
assessment of the included studies was conducted based
on the Newcastle-Ottawa Scale (NOS) criteria (targeting
the quality of non-randomized studies) [13]. The NOS cri-
teria apply a “star” rating system ranges from 0 (worst) to
8 (best) for the judgment of methodological quality, which
was based on selection, comparability, and outcome. We
set 5 star as the cutoff value of our analysis, as article with
NOS ≥5 was qualified enough for a meta-analysis. Con-
flicting evaluations or inconsistent data from the eligible
studies were resolved through discussion or by asking a
verdict by a third arbitrator (DR Xiu).
Statistical analysis
The effects of K-ras gene mutations on OS were assessed
using the overall HR and 95 % confidence interval (95 %
CI). Data from Kaplan-Meier survival curves were col-
lected through Engauge Digitizer version 4.1 (free software
downloaded from http://sourceforge.net) when the HR was
not provided, and the minimum and maximum follow-up
periods were obtained from the articles. Heterogeneity be-
tween studies was estimated using both the Cochran’s Q
statistic (which considered significant at P < 0.10 [14]). A
fixed effects model (the Mantel-Haenszel method) was
used for the calculation of Crude HRs when there was no
statistically significant heterogeneity (Q test with P > 0.10).
Otherwise, the random effects model (the DerSimonian
Laird method) was conducted. The significance of the
pooled estimate was determined using the Z test.
Subgroup analyses were performed based on ethnicity,
publication years, detection methods, tumor resectability,
and treatment methods. Besides, a sensitivity analysis was
performed using the sequential omission of individual
studies to assess the quality and consistency of the results.
Begg’s funnel plots were also constructed to evaluate the
effect of publication bias on this study, and Egger’s linear
regression test was further performed to evaluate the sym-
metry of these funnel plots [15]. All meta-analyses were
calculated using Stata software 12.0 (Stata Corp LP,
College Station, TX, USA). All tests were two-sided
with P < 0.05 as statistically significant.
Results
Description and quality assessment of studies
A total of 1147 studies meeting the search strategy were
initially identified, and 699 duplicates were excluded,
leaving 448 articles. After a review of their titles and ab-
stracts, 387 articles were excluded. Another 61 articles
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were excluded after full text identification, leaving 17 stud-
ies for tissues detection and 4 studies for plasma detection
that met our criteria for this meta-analysis (Fig. 1). As for
tissue detection, a total of 2249 (1302 males and 947 fe-
males) pancreatic cancer patients, including 1261 patients
in the K-ras mutant group and 988 patients in the wild-
type group, were involved in present meta-analysis. A
summary of the characteristics and methodological quality
of the included studies are shown in Table 1. Four studies
with a total of 225 patients were included in the analysis
of plasma detection, which are listed in Table 2.
Quantitative data synthesis
The meta-analysis results suggested that K-ras gene mu-
tations were significantly associated with poorer OS
(HR = 1.51, 95 % CI 1.32–1.72, P < 0.001; P for hetero-
geneity 0.62, fixed effects model) (Fig. 2). HRs for OS
comparing the K-ras mutant type group with the wild-
type group is summarized in Table 3.
Results from a subgroup analysis by ethnicity indicated
that K-ras mutant patients had poorer OS among both
Caucasia and n Asian populations (HR = 1.35, 95 % CI
1.10–1.64, P = 0.000 % and HR = 1.65, 95 % CI 1.38–1.97,
P < 0.001, respectively; both P for heterogeneity >0.1, fixed
effects models). Because the publication number of K-ras-
related articles focus on pancreatic cancer was elevated
significantly after 2010, we chose the year of 2010 as a cut-
off point. The further stratified analyses by publication
year suggested that, despite no significant association
between K-ras mutation and OS prior to 2010, which
included the year of 2010 (HR = 1.27, 95 % CI 0.96–1.69,
P = 0.098; P for heterogeneity >0.1, fixed effects model),
the K-ras mutant patients had worse OS than the patients
without K-ras mutations after 2010 (HR = 1.58, 95 % CI
1.36–1.83, P < 0.001; P for heterogeneity >0.1, fixed effects
model). With the exception of the study by Kinugasa H
[28], which failed to provide detailed information about
the treatment, subgroup analyses by the respectability
Fig. 1 Flowchart of the search history in this meta-analysis
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(those who underwent an operation) of cancer indicated
that K-ras mutant patients had worse OS whether the can-
cers were resectable or not (HR = 1.44, 95 % CI 1.19–1.74,
P < 0.001 and HR = 1.57, 95 % CI 1.30–1.91, P < 0.001, re-
spectively; both P for heterogeneity >0.1, fixed effects
models). Additionally, the subgroup analysis according to
treatment methods revealed a statistically significant dif-
ference in OS between the K-ras gene mutant group and
the wild-type group (operation only: HR = 1.35, 95 % CI
1.09–1.69, P = 0.005 %; chemotherapy only: HR = 1.57,
95 % CI 1.30–1.91, P < 0.001; operation and chemother-
apy: HR = 1.71, 95 % CI 1.18–2.48, P = 0.005, respectively;
All P for heterogeneity >0.1, fixed effects models). Finally,
a subgroup analysis according to gene detection methods
also showed that the K-ras gene mutation was significantly
associated with poorer OS (HR = 1.46, 95 % CI 1.22–1.75,
Table 1 Characteristic summary of studies included in the meta-analysis
The author Year Country Ethnicity Age (years) Gender (M/F) Treatment Detection method Outcome NOS




Boeck, S [17] 2013 Germany Caucasians 64 (32–78) 105/68 Chemotherapy Pyrosequencing OS 7
Kim, S.T. [18] 2011 Korea Asians ≥60, n = 84
< 60, n = 52
99/37 Chemotherapy DS OS 7
Ogur, T [19] 2014 Japan Asians 65 (35–84) 146/96 Chemotherapy RT-PCR OS 6
Schultz, N.A. [6] 2012 Denmark Caucasians 63 (33–85) 88/82 Operation DS OS 7
Shin, S.H. [20] 2013 Korea Asians 60 (22–78) 139/95 Operation PCR-RFLP OS 8
Sinn, B.V. [7] 2014 Germany Caucasians ≥65, n = 81;
<65, n = 72
84/69 Operation DS OS 7





2010 Canada Caucasians 62 (40–85) 64/53 Chemotherapy PCR and BS OS 7





lkeda, N [23] 2001 Japan Asians 63.7 (47–80) 37/11 Operation and
chemotherapy
DS OS 7
Kwon, M.J. [24] 2011 Korea Asians 63 (45–86) 37/35 Operation and
chemotherapy
RT-PCR OS 8
Lee, J [25] 2007 Korea Asians ≥60, n = 47;
<60, n = 19
51/15 Chemotherapy DS OS 5
Oh, D.Y. [26] 2012 Korea Asians 57.3 (39–77) 24/16 Chemotherapy DS OS 6
Salek, C [27] 2009 Czech Caucasians 63 ± 10.5
(40–84)
28/25 Chemotherapy GenoScan OS 6
Kinugasa, H [28] 2015 Japan Asians 66 (47–85) 54/21 NR Digital PCR OS 7
Talar-Wojnarowska,
R [29]
2005 Poland Caucasians 47–76 10/16 Operation PCR-RFLP OS 6
DS direct sequencing, BS bidirectional sequencing, NR not reported, RT-PCR reverse transcription polymerase chain reaction, PCR-RFLP polymerase chain reaction-
restriction fragment length polymorphism, NOS Newcastle-Ottawa Scale (NOS) criteria (targeting the quality of non-randomized studies)
Table 2 Characteristic summary of studies that detected the K-ras gene in plasma
Author Year Country Ethnicity Age (years) Gender (M/F) K-ras (mutant/wild) HR (95 % CI) Outcome Sites
Kinugasa, H [28] 2015 Japan Asians 66 (47–85) 54/21 47/28 1.84 (1.1–3.25) OS 12, 13, 61
Castells, A [12] 1999 Spain Caucasian NR NR 12/32 1.51 (1.02–2.23) OS 12
Chen, H.H. [30] 2010 China Asians 60 (37–78) 57/34 30/61 7.39 (3.7–14.9) OS 12
Yadama, T [31] 1998 Japan Asians 63.9 (35–78) 11/4 11/4 4.7 (2.8–21.2) OS 12
Combined 2.23 (1.69–2.95) OS
NR not reported, Sites sites of K-ras mutations involved, such as codons 12, 13, and 61
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P < 0.001 and HR = 1.57, 95 % CI 1.29–1.90, P = 0.005, re-
spectively; P for heterogeneity >0.1, both fixed effects
models) (Table 4).
To further evaluate the prognostic value of K-ras mu-
tations in pancreatic cancer, we listed characteristics
from the four studies that focused on the relationship
between plasma K-ras mutations and pancreatic cancer
prognosis [12, 28, 30, 31]. K-ras mutations in all four
studies revealed a significant association with poorer OS,
and the combined HR also indicated a strong association
(HR = 2.23, 95 % CI 1.69–2.95, P < 0.001; P for hetero-
geneity <0.1, random effects model), (Table 2).
Fig. 2 Forest plots for the relationships between K-ras gene mutations and prognosis in patients with pancreatic cancer
Table 3 The hazard ratios for overall survival comparing K-ras mutations with the wild-type in the included studies
The author Year K-ras (mutant/wild) HR (95 % CI) P value Sites
Allison, D.C. [16] 1998 64/12 0.70 (0.35–1.43) 0.330 NR
Boeck, S [17] 2013 121/52 1.68 (1.17–2.41) 0.005 12, 13
Kim, S.T [18] 2011 71/65 1.68 (1.18–2.39) 0.001 12, 13
Ogur, T [19] 2014 214/28 1.76 (1.03–3.01) 0.040 12
Schultz, N.A. [6] 2012 136/34 1.15 (0.75–1.77) 0.510 12, 13, 61
Shin, S.H. [20] 2013 126/108 1.63 (1.13–2.34) 0.001 12, 13
Sinn, B.V. [7] 2014 105/48 1.68 (1.07–2.62) 0.023 12, 13, 61
Franko, J [21] 2008 31/19 3.28 (1.09–9.90) 0.035 12, 13, 1
da Cunha Santos, G [22] 2010 92/25 0.68 (0.33–12.42) 0.300 12, 13
Fensterer, H [5] 2013 45/21 1.28 (0.62–2.64) 0.180 12, 13
lkeda, N [23] 2001 33/15 1.83 (0.87–3.88) 0.317 12
Kwon, M.J. [24] 2011 34/38 1.65 (0.90–3.01) 0.159 12, 13, 1
Lee, J [25] 2007 33/33 1.51 (1.01–2.66) 0.030 12
Oh, D.Y. [26] 2012 19/21 2.03 (0.43–9.61) 0.158 12, 13
Salek, C [27] 2009 36/17 0.83 (0.38–1.83) 0.636 12, 13
Kinugasa, H [28] 2015 47/28 1.59 (0.88–3.07) 0.124 12, 13, 61
Talar-Wojnarowska, R [29] 2005 20/6 0.87 (0.23–3.29) 0.580 12
NR not reported, Sites sites of K-ras mutations involved, such as codons 12, 13, and 61
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Evaluation of heterogeneity and publication bias
The results of the sensitivity analysis suggested that no
individual studies significantly affected the pooled HRs
(Fig. 3). The shapes of Begg’s funnel plots and the result
of Egger’s linear regression test (P = 0.356) did not reveal
evidence of obvious publication bias (Fig. 4).
Discussion
In our work, the combined HR for 17 studies evaluating
the correlation between K-ras mutations and overall sur-
vival of patients with pancreatic cancer was 1.51 (95 %
CI 1.32–1.72, P = 0.000), which indicated that K-ras
mutations have negative prognostic value in pancreatic
cancer. In our subgroup analyses, the HR for both Cau-
casian and Asian populations implied that pancreatic
cancer patients harboring K-ras mutations also tend to
get a worse survival. Furthermore, subgroup analyses
according to tumor resectability and the treatment and
detection methods of K-ras still revealed that K-ras gene
mutations were strongly correlated with poorer progno-
ses in patients with pancreatic cancer. Notably, the K-ras
mutation was only significantly correlated with poorer
OS after 2010 (not included 2010). However, the com-
bined HR of K-ras mutation before is 1.27, which still
Table 4 Subgroup analysis of the association between K-ras mutations and overall survival of patients with pancreatic cancer
Subgroup No. of patients with
mutant K-ras
No. of patients without
mutant K-ras
HR (95 % CI) Heterogeneity I2 (%) Heterogeneity
P value
Ethnicity
Caucasian 650 234 1.35 (1.10–1.63) 28.0 0.195
Asian 586 327 1.65 (1.32–1.72) 0.0 0.136
Publication year
Before 2010 309 127 1.27 (0.96–1.69) 33.1 0.175
After 2010 927 434 1.58 (1.36–1.83) 0.0 0.963
Tumor resectability
Resectable 594 301 1.44 (1.19–1.74) 14.3 0.315
Unresectable 586 241 1.57 (1.30–1.91) 0.0 0.686
Treatment
Operation 451 208 1.35 (1.09–1.69) 35.7 0.183
Chemotherapy 586 241 1.57 (1.30–1.91) 0.0 0.686
Operation + chemotherapy 143 93 1.71 (1.18–2.48) 0.0 0.574
Detection methods
Sequencing 428 235 1.57 (1.29–1.90) 0.0 0.644
Other methods 808 326 1.46 (1.22–1.75) 2.0 0.421
Fig. 3 Sensitivity analysis for the pooled HRs of the differences in OS between K-ras gene mutations and wild-type pancreatic patients
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supports our conclusion. The reason why the insignifi-
cant association may be the small sample sizes of the
studies.
Detection of K-ras mutations in circulating DNA,
which can be performed before and after operation, is
much more convenient than the application of tissue
samples. The occurrence or absence of K-ras mutations
in the peripheral blood might reflect different tumor
stages [32]. The detection of K-ras mutations in the per-
ipheral blood could reflect the tumor burden of individ-
ual PC patients, and in turn predict a prognosis. During
the analysis of plasma samples, all the four studies have
a significant association between K-ras mutations and
poorer OS, and a higher combined HR of 2.23 further
agree with the prognostic value of mutant K-ras. All the
data above demonstrated the feasibility of K-ras muta-
tions as a predictor of prognosis of PC patients. It is of
great significance to one of the most malignant tumor,
which has a 5-year survival rate of less than 5 %. For pa-
tients with expression of K-ras mutations, more frequently
postoperative re-examination and follow-up survey may
be needed and more proactive therapeutic schedule of
postoperative adjuvant therapy may be necessary when
compared to the negative expressed patients.
Other than a useful prognosis predictor of pancreatic
cancer, the detection of mutant K-ras may make it possible
to develop new therapeutic approaches. As a member of
the Ras gene family, K-ras plays a key role in Ras/mitogen-
activated protein kinase signaling. Somatic mutation in K-
ras mutations have been shown to be early events in the
carcinogenesis of human pancreatic cancer [3, 4]. To
blockade the Ras signaling pathway, it has been pro-
posed that cancer vaccines that stimulate immunity
against mutant Ras proteins and antisense therapy that
blocks the translation of mutant Ras gene could be ap-
plied in the treatment after operation [33]. Evidence
has indicated that K-ras expression and the growth and
invasiveness of PC cell lines can be inhibit by K-ras
antisense oligodeoxynucleotide (K-ras-ASODN). Simi-
lar effects also can be identified in the models of PC by
intraperitoneal injection of adenovirus [34].
This study has several limitations. First, current sam-
ples of available studies were relatively small with 17 for
tissue detection and only 4 for plasma detection. How-
ever, such number is enough for a meta-analysis, and we
even give a subgroup analysis of tissue detection studies.
Second, the definition of resectability (between centers
and surgeons) and the treatment after operation like
chemotherapy may be different between the studies.
Such limitation is hard to control for the treatment of
pancreatic cancer is still under controversy. Lastly, data
about tumor stage or sample size were not provided in
most included articles, and the divide of stage for ana-
lysis was also not unified, which prevent a further sub-
group analysis. Despite those shortcomings, the effect of
K-ras on survival was consistent in nearly all of the in-
cluded studies, and no studies reported a favorable out-
come in patients with K-ras mutations.
Conclusions
In conclusion, K-ras gene mutations are associated with
a poorer prognosis in patients with pancreatic cancer. It
may represent a useful prognostic factor to stratify pa-
tients with high risk and in developing specific treat-
ments for these patients in clinical applications.
Fig. 4 Begg’s funnel plots of the prognostic role of K-ras gene mutations in pancreatic cancer patients. Each point represents a separate study for
the indicated association. Log(HR) natural logarithm of HR; horizontal line means the magnitude of the effect. Note: A funnel plot with ~95 %
confidence limit was used (Egger’s test: t = −0.95, P = 0.356)
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